Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

Status unconfirmed · Phase 1

Conditions studied: Chronic Kidney Diseases, Hyperkalemia

In brief

This study hypothesizes that the administration of Sodium zirconium cyclosilicate in CKD patients with hyperkalemia while avoiding dietary potassium restriction will normalize their serum potassium levels. Additionally, we aim to assess the effects of a high potassium diet on renal function, endothelial function, acidosis, systemic inflammatory status and gut microbiota.

Key facts

Study ID

NCT04727840

Run by

Brigham and Women's Hospital

People needed

20

Starts

2021-03-15

Expected to finish

2022-01-15

Last updated by the study team

2021-02-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women over the age of 18
• CKD stage 3-4 with an estimated GFR less or equal to 45 mL/min but greater than 15 mL/min
• Serum potassium level ≥5 mEq/L on two blood tests in the past 3 months but less than 6.5mEq/L

You may not qualify if…

• On dialysis
• Have been on SZC in the past 3 months
• Reside in a nursing home
• Pregnant patients
• Patients with known cognitive disability
• History of bowel disease such as but not limited to short bowel syndrome, bowel obstruction, inflammatory bowel disease

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.